Alcohol Withdrawal Syndrome Clinical Trial
Official title:
A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Phenobarbital and Ketamine Adjunctive Therapies in the Treatment of Alcohol Withdrawal Syndrome
The goal of this study will aim to determine if adding phenobarbital or ketamine to a symptom-triggered benzodiazepine regimen decreases the rate of intensive care unit admissions during the treatment of alcohol withdrawal syndrome when compared to symptom-triggered benzodiazepine therapy alone.
The primary objective of this study is to compare phenobarbital and ketamine adjunctive
therapies to lorazepam-based therapy in the treatment of acute alcohol withdrawal syndrome.
It is hypothesized that the use of an alternative agent, either phenobarbital or ketamine,
when used as an adjunct to symptom-triggered lorazepam therapy will significantly reduce the
rate of intensive care unit admissions and thereby reduce the total cost associated with
hospital admission for treatment of alcohol withdrawal syndrome.
Enrolled patients will be admitted to Santa Barbara Cottage Hospital where they will be
monitored with continuous pulse oximetry and cardiac telemetry. They will remain hospitalized
while undergoing study-guided therapy in addition to supportive care for acute alcohol
withdrawal syndrome. Patients will undergo standard of care therapy with lorazepam
symptom-triggered therapy regardless of study participation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03033823 -
MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
|
Phase 3 | |
Completed |
NCT02146716 -
Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.
|
N/A | |
Completed |
NCT01637415 -
The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS)
|
N/A | |
Completed |
NCT04973202 -
Portrayal of Hospital Alcohol Detoxification in France
|
||
Terminated |
NCT02052440 -
Preventing Alcohol Withdrawal Syndrome With Oral Baclofen
|
Phase 3 | |
Completed |
NCT01652326 -
Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome
|
N/A | |
Recruiting |
NCT03235531 -
Assessment of Valproate on Ethanol Withdrawal
|
Phase 4 | |
Completed |
NCT00146471 -
Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome
|
Phase 3 | |
Completed |
NCT02090504 -
Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
|
Phase 4 | |
Completed |
NCT03012815 -
Gabapentin for Alcohol Withdrawal Syndrome
|
Phase 4 | |
Completed |
NCT05438641 -
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
|
||
Completed |
NCT00249366 -
Treatment of Alcohol Withdrawal in Hospital Patients
|
Phase 4 |